Market Outlook

By 2035, the U.S. Remote Diabetes Monitoring Devices Market is estimated to reach approximately USD 34.14 billion, expanding at an aggressive CAGR of 15.40% during the forecast period 2026–2035. The market is estimated at USD 8.15 billion in 2025, with historical analysis covering 2021–2024. Values in this report are expressed in USD billions.

The U.S. remote diabetes monitoring devices industry is moving from a specialist diabetes-technology category into a mainstream chronic-care infrastructure market. Continuous glucose monitoring systems, connected blood glucose meters, implantable glucose sensors, professional CGM solutions, cloud-connected monitoring peripherals, mobile applications, clinician dashboards, and remote patient monitoring ecosystems are increasingly becoming integrated components of diabetes management rather than optional adjuncts.

The addressable population is substantial. U.S. public-health data indicate approximately 40.1 million people are living with diabetes, while more than 115 million adults have prediabetes. The economic burden is also unusually high, with diabetes-related healthcare expenditure and productivity losses estimated at more than USD 400 billion annually. These figures create a strong economic incentive for payers, health systems, endocrinology practices, employers, and primary-care organizations to identify glycemic deterioration earlier and manage patients outside expensive acute-care settings.

The market expanded from an estimated USD 4.55 billion in 2021 to USD 7.08 billion in 2024, reflecting rapid CGM adoption, broader pharmacy-channel distribution, expansion of Medicare access, increasing use among people with type 2 diabetes, and greater acceptance of smartphone-connected monitoring. The market reached approximately USD 8.15 billion in 2025, supported by longer-wear sensors, increasing interoperability with insulin-delivery systems, expansion into non-insulin-treated populations, and greater use of glucose data within remote care programs.

The fundamental growth story is no longer limited to replacing fingerstick testing. The commercial value pool is shifting toward continuous data generation, longitudinal analytics, alerting, caregiver connectivity, remote therapeutic decision support, and integration with broader digital diabetes-management ecosystems. The device increasingly serves as the front end of a recurring data relationship between the patient, clinician, payer, and manufacturer.

This transformation materially changes competitive economics. Conventional glucose meters historically generated revenue largely through strips and lancets. Modern remote monitoring platforms monetize recurring sensors, data services, connected accessories, clinical workflow integration, software-supported decision tools, and in some cases remote monitoring services. The resulting market is increasingly attractive because the clinical use cycle is persistent, data-rich, recurring, and closely connected to medication optimization.

From 2026 through 2035, market growth will increasingly be determined by how far CGM and connected monitoring penetrate the much larger population of people with type 2 diabetes who do not use intensive insulin therapy. The expansion of over-the-counter glucose sensing, longer sensor wear, pharmacy availability, Medicare and commercial payer coverage, primary-care prescribing, and AI-assisted interpretation could move remote diabetes monitoring from millions of intensive-management users toward a substantially broader chronic metabolic-care population.

 

Introduction

According to the U.S. Remote Diabetes Monitoring Devices Market Report, remote monitoring is becoming one of the most strategically important layers of the American diabetes-care ecosystem because diabetes management depends heavily on information generated between physician visits.

Traditional episodic HbA1c testing provides valuable long-term information but does not show the daily effects of meals, medications, exercise, illness, sleep, stress, hypoglycemia, or treatment adherence. Connected glucose-monitoring technologies address this visibility gap by producing data that can be interpreted remotely and acted upon before the next scheduled clinic visit.

The U.S. market has several structural advantages supporting adoption. Smartphone penetration is high, diabetes-specialist infrastructure is mature, pharmacy distribution for diabetes technologies is well developed, Medicare covers qualifying CGM populations, remote physiologic monitoring has an established reimbursement framework, and integrated health systems are increasingly investing in virtual chronic-care models.

Clinical demand is also widening. Remote diabetes monitoring historically centered on people with type 1 diabetes and individuals with insulin-intensive type 2 diabetes. The next phase is extending monitoring into basal-insulin users, people with type 2 diabetes treated with non-insulin medications, individuals at elevated hypoglycemia risk, gestational diabetes management, post-discharge care, and selected metabolic-health populations.

The economics are particularly compelling for high-risk patients. Poor glycemic control contributes to emergency visits, cardiovascular disease, kidney disease, neuropathy, retinal complications, infections, amputations, and hospital utilization. A remote monitoring platform capable of identifying persistent hyperglycemia, recurrent hypoglycemia, medication-response problems, or adherence deterioration can allow clinicians to intervene before complications become more expensive.

The U.S. market is therefore moving toward a longitudinal-care model in which a glucose sensor or connected meter is not simply a measuring device. It is becoming an entry point into medication management, behavioral coaching, risk stratification, population health, caregiver engagement, and automated insulin delivery.

Another important change is procurement. Endocrinology practices remain influential, but purchasing and prescribing decisions increasingly involve large health systems, pharmacy benefit structures, Medicare Advantage plans, commercial insurers, primary-care organizations, virtual diabetes companies, employers, retail pharmacies, and value-based care organizations. Manufacturers must therefore demonstrate not only measurement accuracy, but also persistence, workflow efficiency, patient engagement, interoperability, coverage access, and measurable clinical outcomes.

The market is expected to become increasingly concentrated around connected ecosystems rather than standalone products. Device companies capable of linking sensing, cloud data, analytics, insulin-delivery integration, patient applications, clinician portals, and population-management tools will have a strategic advantage over companies selling isolated measurement hardware.

 

Key Market Drivers: What’s Fueling the U.S. Remote Diabetes Monitoring Devices Market Boom?

The most powerful growth driver is the scale of diabetes itself. Approximately 40 million Americans are estimated to have diabetes, while the prediabetes population exceeds 115 million adults. The potential user base is therefore far larger than the current population using continuous or digitally connected monitoring technologies.

A second driver is the transition from fingerstick-centered glucose management to continuous information. Conventional self-monitoring produces isolated readings and requires the patient to decide when to test. CGM creates an ongoing picture of glucose direction, variability, time in range, overnight patterns, post-meal excursions, and hypoglycemia. This substantially increases the clinical information available between office visits.

The third driver is broader eligibility beyond type 1 diabetes. Insulin-treated type 2 diabetes represents a substantial expansion opportunity, but the larger strategic frontier is non-insulin-treated type 2 diabetes. Many of these patients have historically relied mainly on periodic laboratory testing and occasional fingersticks. As evidence grows around the behavioral and medication-management value of glucose-pattern visibility, manufacturers are positioning remote monitoring for a much broader type 2 population.

Over-the-counter access reinforces this transition. The FDA’s clearance of OTC CGM platforms has created a new distribution model that can reach consumers without the traditional prescription pathway in eligible populations. This reduces one of the most important historical barriers to glucose-sensor adoption: dependence on specialist prescribing and payer authorization.

Longer sensor wear is another important growth catalyst. A shift from shorter-duration sensors toward 14-day, 15-day, and even one-year implantable monitoring creates the potential to reduce application burden, improve continuity, lower replacement frequency, and improve persistence. Longer wear is particularly relevant for older adults and people with type 2 diabetes who may view frequent sensor replacement as an unnecessary inconvenience.

Reimbursement remains central to U.S. adoption. Medicare coverage of CGM for qualifying patients materially expanded the commercial market, particularly because older adults account for a disproportionately large share of diabetes prevalence. Remote physiologic monitoring reimbursement also supports care models in which clinical teams review device-generated physiologic data and interact with patients remotely.

Health-system labor economics provide another growth driver. Endocrinologists are limited in number relative to the diabetes population. Remote monitoring allows trained nurses, pharmacists, diabetes-care and education specialists, advanced practice clinicians, and centralized monitoring teams to prioritize patients based on data rather than requiring every patient to receive identical visit frequency.

The rise of value-based care is equally important. Providers accepting greater responsibility for total cost of care have a stronger incentive to identify patients at risk of deterioration before an emergency department visit or hospitalization occurs. Connected glucose data can provide a recurring signal that complements laboratory results and claims-based risk models.

Rural healthcare represents a particularly important opportunity. Diabetes prevalence is generally higher in many nonmetropolitan populations, while endocrinology access is often lower. Remote monitoring helps separate glucose-data acquisition from the physical location of the specialist, enabling regional centers to support patients across much wider geographic areas.

Pharmacy-channel expansion also improves accessibility. Moving CGM fulfillment toward retail and specialty pharmacy channels can simplify prescribing, reduce durable-medical-equipment friction, improve refill visibility, and allow manufacturers to engage patients through pharmacy benefit pathways.

Finally, diabetes monitoring is increasingly connected to automated therapy. CGM data can communicate with compatible insulin pumps, smart insulin systems, dosing tools, and decision-support applications. This interoperability increases the strategic value of the sensor because the monitoring device becomes a control input for therapy rather than merely a display mechanism.

 

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation in the U.S. remote diabetes monitoring devices market is increasingly centered on reducing user burden while increasing the clinical usefulness of every day of data collected.

Longer sensor wear is one of the most visible innovation themes. Wear duration directly influences user convenience, annual replacement frequency, supply-chain requirements, and total episode economics. The emergence of approximately 15-day wearable systems and an implantable CGM capable of functioning for up to one year illustrates how device companies are competing on persistence rather than measurement accuracy alone.

Miniaturization remains important. Smaller sensors, simplified applicators, reduced warm-up periods, factory calibration, waterproof designs, discreet wear, and smartphone-first interfaces reduce friction and make CGM more acceptable to patients who do not identify themselves as intensive diabetes-technology users.

Interoperability is becoming another major competitive battleground. Sensors are increasingly designed to communicate with automated insulin-delivery platforms, smart pens, mobile applications, clinician portals, caregiver applications, and third-party diabetes-management systems. Manufacturers that become preferred sensing partners across multiple insulin-delivery ecosystems can increase both utilization and switching barriers.

AI-assisted interpretation represents the next layer of differentiation. The clinical problem is shifting from insufficient data to excessive data. A physician managing hundreds or thousands of diabetes patients cannot manually review every glucose trace. Analytics that identify recurrent nocturnal hypoglycemia, postprandial excursions, worsening time in range, medication-response changes, or high-risk variability can help convert continuous information into prioritized clinical action.

Workflow design is therefore becoming as important as sensor performance. Health systems increasingly evaluate whether data can flow into existing clinical systems, whether clinicians can efficiently identify patients requiring intervention, and whether remote-review processes create manageable rather than excessive alert volume.

Another area of innovation is expansion into non-insulin-treated type 2 diabetes. Products designed for this population require different value propositions. Severe hypoglycemia alerting may be less central than identifying dietary responses, medication effectiveness, post-meal excursions, exercise effects, and sustained hyperglycemia. This is driving greater differentiation between intensive diabetes-management CGM and broader metabolic-monitoring products.

Implantable sensing represents a differentiated technology pathway. A one-year implanted sensor substantially changes replacement economics and adherence requirements relative to disposable wearable sensors. The tradeoff is a clinician insertion and removal procedure, meaning commercial adoption depends on whether the reduction in day-to-day burden offsets procedural complexity.

Remote monitoring is also expanding beyond glucose alone. Connected blood pressure monitors, scales, activity devices, ketone meters, medication-adherence tools, and other physiologic peripherals can provide additional context for high-risk diabetes patients with obesity, hypertension, cardiovascular disease, kidney disease, or heart failure.

Device reliability and software safety will remain critical. As clinical decisions become increasingly dependent on mobile applications, wireless communication, algorithms, and cloud infrastructure, manufacturers must address cybersecurity, sensor failures, app interruptions, alarm reliability, compatibility changes, and software-update governance with the same seriousness historically applied to physical device performance.

The strongest future platforms will likely combine low-burden sensing, high-quality connectivity, clinically actionable analytics, broad payer access, interoperable therapy integration, and scalable provider workflows.

 

Segmentation Insights

The U.S. Remote Diabetes Monitoring Devices Market is segmented on the basis of product type, patient type, monitoring model, end user, and region.

 

By Product Type

Real-Time Continuous Glucose Monitoring Systems

Real-time CGM systems represent the largest and most strategically important product segment. These devices continuously sense interstitial glucose and transmit readings to a smartphone, receiver, compatible insulin-delivery system, or cloud platform.

The category benefits from recurring sensor consumption, strong clinical adoption in type 1 diabetes, expanding use in type 2 diabetes, and increasingly broad connectivity with insulin pumps and healthcare applications. Abbott and Dexcom represent the strongest commercial scale in U.S. CGM, while Medtronic maintains an important position through its integrated diabetes technology ecosystem.

Growth through 2035 will be driven increasingly by longer wear, simplified application, expanded reimbursement, pharmacy access, interoperability, and penetration into patients not using intensive insulin therapy.

Intermittently Scanned and Flash Glucose Monitoring Systems

Flash glucose monitoring established an important bridge between conventional blood glucose testing and fully automated real-time CGM. These platforms historically required users to actively scan sensors, although newer systems increasingly incorporate automatic data transmission and alarms.

The segment remains important because of its large installed base, relatively accessible economics, established reimbursement, and broad familiarity among U.S. diabetes professionals. Competitive pressure from fully real-time systems is pushing the category toward greater automation and connectivity.

Implantable Continuous Glucose Monitoring Systems

Implantable CGM represents a smaller but strategically differentiated segment. Eversense 365 demonstrated the feasibility of a single sensor supporting approximately one year of glucose monitoring for eligible adults.

The technology could appeal to patients frustrated by frequent sensor replacement, adhesive problems, repeated application, device loss, or lifestyle disruption. Commercial growth will depend on clinician availability for insertion and removal, reimbursement economics, patient awareness, integration with automated insulin-delivery systems, and performance relative to disposable CGM.

Connected Blood Glucose Monitoring Devices

Connected blood glucose meters remain important despite rapid CGM growth. They provide lower-cost monitoring for people who do not require continuous sensing and remain relevant for therapy confirmation, occasional monitoring, backup testing, gestational diabetes, and selected primary-care populations.

Modern devices increasingly transfer readings to smartphone applications or cloud platforms through Bluetooth or cellular connectivity. This enables remote physician review without requiring a continuous sensor.

The category is mature and faces pricing pressure, but connected meters can remain commercially attractive when bundled into payer, employer, virtual-care, or population-health programs.

Remote Monitoring Hubs and Multi-Parameter Diabetes Devices

This category includes connected blood pressure monitors, weight scales, ketone-testing systems, cellular gateways, home-monitoring hubs, and other connected physiologic devices used within diabetes-management programs.

The opportunity is strongest among patients with diabetes plus hypertension, obesity, chronic kidney disease, cardiovascular disease, pregnancy-related risk, or multiple chronic conditions. These patients benefit from monitoring programs that examine metabolic deterioration in a broader physiologic context rather than glucose alone.

 

By Patient Type

Type 1 Diabetes

Type 1 diabetes remains the most technology-intensive patient segment. U.S. data indicate approximately 2.1 million people have diagnosed type 1 diabetes, including adults, children, and adolescents.

CGM has become deeply integrated into type 1 care because treatment decisions require continuous balancing of insulin, food, activity, illness, and hypoglycemia risk. Connectivity with automated insulin-delivery systems makes continuous monitoring particularly valuable.

Although type 1 represents a relatively small share of the total diabetes population, device utilization per patient is high, supporting substantial recurring revenue.

Insulin-Treated Type 2 Diabetes

Insulin-treated type 2 diabetes is one of the largest near-term growth pools. Patients using multiple daily insulin injections or basal insulin require improved visibility into glucose response and may benefit substantially from continuous monitoring.

This segment is strategically attractive because the population is much larger than type 1 diabetes and includes many Medicare beneficiaries. Older adults with diabetes also have greater vulnerability to hypoglycemia and multiple chronic conditions, increasing the value of remote visibility for clinicians and caregivers.

Non-Insulin-Treated Type 2 Diabetes

Non-insulin-treated type 2 diabetes is expected to represent one of the fastest-growing patient categories through 2035.

Historically, many people in this population used little or no home glucose monitoring. OTC CGM, reduced sensor costs, pharmacy distribution, employer-sponsored metabolic programs, and greater clinical interest in lifestyle-response data are changing that equation.

The commercial opportunity is large because type 2 diabetes accounts for the substantial majority of U.S. diabetes cases. Even moderate penetration can generate billions of dollars in additional annual device demand.

Gestational Diabetes and High-Risk Pregnancy

Pregnancy-associated diabetes monitoring remains smaller by market value but clinically important. Tight glucose management is necessary because maternal hyperglycemia can affect both maternal and fetal outcomes.

Connected meters remain widely used, while CGM adoption is expanding in selected pregnant patients. Remote monitoring can reduce unnecessary office-based review and allow obstetric, maternal-fetal medicine, and endocrinology teams to evaluate glucose patterns more efficiently.

Prediabetes and High-Risk Metabolic Populations

Prediabetes represents a future-facing opportunity rather than the current core medical-device market. More than 115 million U.S. adults are estimated to have prediabetes, creating an enormous potential population for episodic sensor use and metabolic feedback.

Not all individuals with prediabetes require continuous monitoring, and payer reimbursement may remain limited. Nevertheless, OTC sensing and consumer metabolic-health platforms could create a substantial self-pay segment by 2035.

 

By Monitoring Model

Clinician-Prescribed Continuous Remote Monitoring

This remains the core medical model and includes patients using prescribed CGM with data accessible to endocrinologists, diabetes educators, primary-care physicians, and other authorized clinicians.

The model benefits from strong clinical legitimacy, reimbursement infrastructure, and direct integration with medication-management decisions. It will remain the largest segment through the forecast period.

Patient-Managed Monitoring with Cloud Sharing

Many patients primarily manage glucose independently while allowing physicians, caregivers, or family members to access data remotely.

This approach reduces the need for continuous clinical intervention while maintaining a pathway for remote visibility. It is particularly important for pediatric diabetes, older adults, and patients at risk of hypoglycemia.

Structured Remote Patient Monitoring Programs

Structured RPM programs combine connected devices with scheduled clinical review and patient interaction.

Health systems and physician organizations can use such models for patients with poorly controlled diabetes, recent medication changes, frequent admissions, multiple chronic conditions, or high risk of deterioration. Reimbursement support increases the attractiveness of these programs when operational requirements are met.

Professional and Episodic Glucose Monitoring

Professional CGM involves temporary sensor use to characterize glucose patterns for diagnosis, therapy optimization, or treatment evaluation.

This model is particularly relevant to primary care, where clinicians may want the information value of CGM without committing every patient to indefinite sensor use. Episodic use may also become important among non-insulin-treated type 2 patients.

OTC and Direct-to-Consumer Monitoring

OTC glucose sensing changes the traditional prescription pathway and is one of the most important structural developments in the market.

Eligible consumers can purchase devices directly and use glucose information to understand diet, exercise, medication, sleep, and other factors. This segment could attract both people with diabetes and broader metabolic-health consumers, although clinical positioning and regulatory indications differ across products.

 

By End User

Hospitals and Integrated Health Systems

Hospitals and integrated delivery networks are major strategic end users because they manage large diabetes populations across inpatient, ambulatory, specialty, and primary-care settings.

Their priorities include reducing preventable admissions, improving discharge transitions, managing high-risk populations, integrating device data into clinical workflows, and supporting value-based contracts.

Enterprise health systems are increasingly interested in standardized platforms that can support thousands of patients rather than isolated devices prescribed independently by individual physicians.

Endocrinology and Diabetes Specialty Practices

Endocrinology practices remain the clinical center of gravity for advanced diabetes technology.

These providers influence sensor selection, automated insulin-delivery integration, interpretation protocols, payer documentation, and patient education. Companies with strong specialist relationships continue to have a substantial commercial advantage.

Primary Care Practices

Primary care represents a major untapped growth channel because most type 2 diabetes is managed outside endocrinology.

Simplified prescribing, easier interpretation, automated clinical reports, episodic CGM use, and pharmacy distribution can make remote diabetes monitoring increasingly practical in primary care.

Manufacturers capable of reducing the clinical workflow burden may unlock a substantially larger patient pool.

Home Healthcare and Remote Monitoring Providers

Home-based care organizations and RPM providers represent an expanding end-user category, particularly for medically complex patients.

These organizations require reliable data transmission, simple onboarding, cellular or smartphone connectivity, patient support, monitoring dashboards, and escalation protocols.

The combination of diabetes, hypertension, obesity, and cardiovascular comorbidity makes multi-device platforms particularly relevant in this segment.

Pharmacies, Retail Health and Direct-to-Consumer Channels

Retail pharmacies increasingly influence diabetes-device access through product fulfillment, coverage navigation, patient education, and OTC distribution.

This channel is likely to become more important as monitoring moves from specialist-driven medical technology toward broader chronic-care and consumer-access models.

 

Regional Insights: Where the Market is Growing Fastest

The U.S. Remote Diabetes Monitoring Devices Market is geographically segmented into the South, West, Northeast, and Midwest.

Regional adoption differs substantially based on diabetes prevalence, population growth, Medicare enrollment, rurality, health-system consolidation, endocrinologist availability, commercial insurance mix, pharmacy access, broadband and smartphone infrastructure, and concentration of technology-oriented providers.

The South is the largest market in 2025, while the West is expected to record the fastest CAGR through 2035. The Northeast remains a premium market for specialist-driven and integrated health-system adoption, while the Midwest combines large diabetes populations with strong opportunities for rural and regional remote monitoring.

South

The South represents an estimated USD 2.94 billion market in 2025 and is projected to reach approximately USD 11.95 billion by 2035, representing growth of roughly 15.05% annually.

The region includes Texas, Florida, Georgia, North Carolina, South Carolina, Virginia, Maryland, Delaware, Tennessee, Kentucky, Alabama, Mississippi, Louisiana, Arkansas, Oklahoma, and West Virginia, with the District of Columbia forming an additional important healthcare market.

The South is commercially important because it combines some of the largest U.S. state populations with high diabetes burden, substantial obesity prevalence, significant rural populations, and rapidly expanding metropolitan health systems.

Texas is one of the most attractive state markets. Houston, Dallas–Fort Worth, Austin, and San Antonio support large health systems and substantial endocrinology and primary-care networks. The state also has extensive rural areas where remote monitoring can improve access to specialist diabetes expertise. Large employer populations and Medicare growth create additional opportunities for CGM and connected monitoring.

Florida is especially important because of its older population. Diabetes prevalence increases substantially with age, making Florida a high-value market for Medicare-funded CGM, caregiver-connected monitoring, and home-based chronic-care programs. Miami, Tampa, Orlando, Jacksonville, and South Florida support large health-system and physician networks capable of scaling remote monitoring.

Georgia and North Carolina are gaining strategic importance because of population growth, healthcare-system expansion, technology investment, and strong regional medical centers. Atlanta, Charlotte, Raleigh-Durham, and surrounding markets are attractive for employer-sponsored and integrated-care diabetes programs.

Virginia and Maryland combine strong health systems, sophisticated payer environments, major academic institutions, and proximity to federal healthcare infrastructure. These characteristics support adoption of connected monitoring and population-health models.

Tennessee and Kentucky have significant diabetes-related disease burden and established regional health systems. Nashville’s healthcare-services ecosystem also makes Tennessee relevant for the commercialization of virtual-care and remote-monitoring models.

Alabama, Mississippi, Louisiana, Arkansas, West Virginia, and Oklahoma represent important need-driven markets. These states contain communities with high chronic-disease burden and reduced specialist access, creating a strong clinical rationale for remote monitoring. Commercial execution, however, must address affordability, digital access, reimbursement navigation, and patient-support requirements.

South Carolina and Delaware are smaller markets but benefit from aging populations, expanding healthcare delivery, and proximity to larger regional referral networks.

The South is expected to remain the largest regional market through 2035 because remote monitoring addresses two of the region’s most important structural challenges simultaneously: high diabetes burden and uneven access to specialty care.

West

The West represents approximately USD 1.98 billion in 2025 and is projected to reach around USD 9.35 billion by 2035, implying a regional CAGR of approximately 16.79%, the fastest among the four U.S. regions.

The region includes California, Washington, Oregon, Arizona, Nevada, Colorado, Utah, New Mexico, Idaho, Montana, Wyoming, Alaska, and Hawaii.

California is the largest Western state market and one of the most important diabetes-technology markets nationally. Its significance comes from population scale, large integrated health systems, strong commercial insurance, advanced digital-health adoption, major technology companies, and the presence of diabetes-device innovators.

California is also strategically important because both clinicians and consumers tend to adopt connected healthcare technologies relatively early. Large provider organizations can deploy remote diabetes monitoring across primary care, endocrinology, population health, and value-based care programs.

Arizona and Nevada are high-growth opportunities because of rapid population expansion and aging demographics. Both states combine large retirement communities with growing metropolitan healthcare networks, supporting increasing demand for CGM and remote chronic-care programs.

Washington and Oregon have strong integrated-care environments and high digital-health readiness. Health systems in these states are well positioned to use centralized monitoring, clinical analytics, and connected diabetes-management platforms.

Colorado and Utah benefit from comparatively technology-oriented populations, integrated health systems, strong employer markets, and growing specialty-care capacity. These markets are likely to show above-average adoption of consumer-facing and digitally integrated glucose-monitoring products.

New Mexico has a strong need for remote monitoring because of geographic dispersion and uneven specialist availability. Successful programs require solutions capable of functioning across rural settings and diverse patient populations.

Idaho, Montana and Wyoming are smaller markets but represent important use cases for remote specialty support because travel distance can create significant barriers to conventional endocrinology access.

Alaska and Hawaii have unique geographic conditions that strengthen the clinical logic for remote monitoring. Distributed communities and travel requirements make connected diabetes management attractive where healthcare access cannot be efficiently centralized.

The West is expected to gain market share through 2035 as OTC sensing, AI-assisted interpretation, consumer health integration, employer-sponsored metabolic programs, and digitally coordinated chronic care become larger components of market growth.

Northeast

The Northeast represented an estimated USD 1.75 billion in 2025 and is projected to reach approximately USD 6.90 billion by 2035, expanding at a CAGR of about 14.70%.

The region includes New York, Pennsylvania, New Jersey, Massachusetts, Connecticut, Rhode Island, Vermont, New Hampshire, and Maine.

New York represents the largest market in the Northeast due to population density, major academic medical centers, sophisticated health systems, Medicaid and Medicare scale, and high specialist concentration. New York City alone contains a substantial base of endocrinology, primary-care, and hospital-based diabetes-management programs.

Pennsylvania is another major market because of its population size, older demographics in many communities, strong integrated delivery networks, and mix of urban and rural diabetes populations. Philadelphia and Pittsburgh support advanced academic care, while central and western areas create attractive use cases for remote management.

New Jersey benefits from population density, high healthcare spending, major pharmaceutical and medical-technology activity, and proximity to New York and Philadelphia healthcare markets.

Massachusetts is disproportionately influential relative to population because of its academic hospitals, research environment, digital-health ecosystem, and concentration of clinical innovators. New technology can gain physician credibility through adoption and evidence generation at institutions in the Boston market.

Connecticut and Rhode Island provide smaller but high-value markets with strong healthcare access and significant insured populations.

Maine, Vermont and New Hampshire illustrate the remote-monitoring opportunity in geographically dispersed and older populations. Rural communities may face long travel distances for endocrinology care, making connected home monitoring and centralized diabetes-management programs increasingly relevant.

Northeastern growth is expected to remain strong but slightly below the West because the region is more mature and population expansion is slower. However, high health expenditure, specialist density, academic influence, and sophisticated payer structures should sustain premium technology adoption.

Midwest

The Midwest accounted for approximately USD 1.48 billion in 2025 and is projected to reach about USD 5.94 billion by 2035, representing a CAGR of approximately 14.91%.

The region includes Illinois, Ohio, Michigan, Indiana, Wisconsin, Minnesota, Missouri, Iowa, Kansas, Nebraska, North Dakota, and South Dakota.

Illinois is the largest Midwest market, led by the Chicago metropolitan area. Large academic systems, integrated provider networks, employer populations, and specialty practices create a substantial addressable market for CGM and remote diabetes management.

Ohio has a major diabetes-care infrastructure supported by large health systems across Cleveland, Columbus, Cincinnati, and other metropolitan areas. Integrated providers can scale monitoring through specialist and primary-care pathways.

Michigan and Indiana represent sizable opportunities because of chronic-disease prevalence, large insured populations, established hospital systems, and substantial type 2 diabetes burden.

Minnesota is strategically distinctive because of its medtech ecosystem, advanced health systems, and healthcare-innovation culture. It remains important for both adoption and industry development.

Wisconsin and Missouri provide steady demand through large regional health systems and a mix of urban and rural patients.

Iowa, Kansas and Nebraska are particularly relevant for remote diabetes management because dispersed populations can create barriers to specialist access. Connected monitoring allows regional centers to manage patients without requiring frequent travel.

North Dakota and South Dakota are smaller markets by revenue but provide a compelling remote-care use case due to low population density and large geographic service areas.

The Midwest should remain a stable and strategically important market through 2035. Adoption may be somewhat more cost-sensitive than in premium coastal markets, making payer coverage, pharmacy access, reliability, patient training, and demonstrable cost savings especially important.

 

Key Market Players

The U.S. Remote Diabetes Monitoring Devices Competitive Landscape is relatively concentrated in continuous glucose monitoring but considerably more fragmented across connected glucose meters, remote-care peripherals, digital diabetes platforms, insulin-delivery integration, and clinical data management.

Abbott and Dexcom represent the two most commercially powerful CGM competitors. Dexcom generated more than USD 3.3 billion of U.S. revenue in 2025, demonstrating the scale already achievable from sensor-based diabetes monitoring in the domestic market. Abbott’s FreeStyle Libre franchise is also one of the largest diabetes-device businesses globally.

Competition is increasingly moving beyond sensor accuracy toward wear duration, price, reimbursement, pharmacy availability, application usability, device interoperability, data analytics, automated-insulin-delivery partnerships, clinician workflow, and access to non-insulin populations.

Relevant companies in the U.S. competitive ecosystem include:

Abbott Laboratories
Dexcom, Inc.
Medtronic plc
Senseonics Holdings, Inc.
Ascensia Diabetes Care
Roche Diabetes Care
LifeScan
Tandem Diabetes Care
Insulet Corporation
Beta Bionics
Sequel Med Tech
DarioHealth
Glooko
Teladoc Health / Livongo
iHealth Labs
AgaMatrix
Trividia Health
Nova Biomedical
embecta Corp.
Withings
Omada Health
One Drop
Welldoc
Validic

Abbott is positioned strongly through FreeStyle Libre and its expanding sensor connectivity and consumer biowearables strategy. Dexcom competes through G7, G7 15 Day, Stelo, Dexcom Clarity, caregiver connectivity, and broad insulin-delivery integration.

Medtronic remains strategically important because monitoring is integrated into its broader insulin-delivery ecosystem. Senseonics offers a differentiated position through Eversense 365 and long-duration implantable sensing.

Ascensia, Roche, LifeScan, AgaMatrix, Trividia and other established glucose-monitoring companies remain relevant through conventional and connected blood glucose monitoring, distribution relationships, and installed patient bases.

Insulet, Tandem Diabetes Care, Beta Bionics and Sequel Med Tech influence the monitoring market through automated insulin-delivery ecosystems in which CGM interoperability is essential.

Glooko, DarioHealth, Welldoc, Teladoc/Livongo, Omada Health and similar digital-care companies influence device purchasing and utilization because they aggregate glucose data into broader patient-management workflows.

Over the forecast period, competitive advantage will increasingly be determined by platform breadth rather than sensor technology alone. Manufacturers able to establish preferred relationships with payers, pharmacy benefit managers, insulin-delivery companies, health systems, employers, and digital diabetes-care providers can build stronger recurring revenue and customer retention.

 

Recent Developments

Recent developments demonstrate how rapidly the U.S. remote diabetes monitoring market is moving toward longer wear, broader eligibility, OTC distribution, and integrated treatment decision support.

In March 2024, the FDA cleared the Dexcom Stelo Glucose Biosensor System as the first over-the-counter CGM in the United States for eligible adults not using insulin. This represented an important structural change because access no longer depended exclusively on a physician prescription for the indicated population.

Abbott subsequently strengthened the OTC market through Libre Rio, designed for adults with type 2 diabetes who do not use insulin, alongside its broader consumer glucose-sensing strategy.

In September 2024, the FDA cleared the Eversense 365 system, enabling continuous glucose monitoring for up to one year in eligible adults with diabetes. The approval materially extended the concept of sensor longevity beyond conventional disposable wear periods and created a differentiated competitive pathway for implantable monitoring.

Medtronic received U.S. regulatory clearance for Simplera CGM in 2024 and subsequent approval for Simplera Sync use with the MiniMed 780G system in 2025, reinforcing the strategic value of simplified, interoperable sensors within automated insulin-delivery platforms.

In April 2025, Dexcom received FDA clearance for the G7 15 Day system for adults with diabetes. Longer wearable duration reduces the annual number of sensor replacements and increases competitive pressure on manufacturers to improve both convenience and total cost of use.

During 2025, the U.S. competitive environment increasingly shifted toward interoperability. Diabetes-device companies expanded partnerships linking sensors with multiple insulin-delivery systems, demonstrating that manufacturers increasingly view CGM as a modular platform rather than a closed proprietary device.

In November 2025, Dexcom received FDA clearance for Smart Basal, a CGM-integrated basal-insulin dosing optimizer for people with type 2 diabetes. This illustrates how glucose monitoring is evolving from passive information display toward software-supported therapeutic decision-making.

In June 2026, FDA clearance expanded Stelo access to children aged two years and older who do not use insulin. The action illustrates continued regulatory expansion of OTC glucose sensing and reinforces the potential for glucose monitoring to reach patient populations traditionally outside intensive diabetes-technology pathways.

At the same time, software-related device corrections and connectivity issues across the industry highlight an important strategic risk. As CGM becomes increasingly dependent on smartphones, applications, wireless connectivity, cloud infrastructure, and automated therapy, software reliability and cybersecurity are becoming core medical-device performance requirements rather than secondary IT considerations.

The commercial environment is therefore entering a new cycle in which competitors must simultaneously improve sensor longevity, accuracy, affordability, usability, software resilience, clinical analytics, and interoperability.

 

Conclusion

The U.S. Remote Diabetes Monitoring Devices Market Size & Share is positioned for substantial expansion from approximately USD 8.15 billion in 2025 to USD 34.14 billion by 2035, representing an estimated 15.40% CAGR during 2026–2035.

The market’s growth is being driven by a combination of exceptionally large disease burden, expanding CGM reimbursement, rising type 2 diabetes adoption, longer sensor wear, OTC availability, growing Medicare demand, increasing remote-care reimbursement, pharmacy distribution, digital-health integration, and the shift toward proactive chronic-disease management.

The commercial opportunity is broader than continuous glucose monitoring alone. The next decade will create demand for connected blood glucose meters, implantable sensors, professional CGM, multi-parameter RPM devices, clinician dashboards, caregiver connectivity, cloud data infrastructure, and analytics that translate raw glucose readings into clinically actionable decisions.

Real-time CGM will remain the largest product category, while non-insulin-treated type 2 diabetes is expected to become one of the most important incremental patient segments. Structured RPM and OTC/direct-to-consumer monitoring will represent particularly attractive emerging monitoring models.

Hospitals and endocrinology practices will continue to influence clinical adoption, but primary care, pharmacies, virtual-care companies, employers, home-health organizations, Medicare Advantage plans, and value-based provider groups will exert increasingly significant purchasing influence.

Regionally, the South will remain the largest market, increasing from approximately USD 2.94 billion in 2025 to USD 11.95 billion by 2035. The West is expected to grow fastest at approximately 16.79% annually, increasing from USD 1.98 billion to USD 9.35 billion. The Northeast should reach approximately USD 6.90 billion, while the Midwest is projected to approach USD 5.94 billion by 2035.

Texas, California, Florida, New York, Pennsylvania, Illinois, Ohio, New Jersey, North Carolina, Georgia, Arizona, Michigan, Massachusetts, Washington, Virginia, and Minnesota are likely to remain particularly important state markets because they combine large diabetes populations, significant healthcare infrastructure, payer scale, specialist networks, or rapid technology adoption.

For manufacturers and investors, the most important competitive question is no longer whether remote glucose monitoring will expand. The central issue is which companies can successfully extend monitoring beyond the traditional intensive-insulin population while preserving clinical value, reimbursement access, patient retention, and sustainable device economics.

For health systems and payers, the question is increasingly whether remote monitoring can be operationalized at scale. Millions of additional glucose readings create little value if clinicians cannot identify which patients require intervention. As a result, data prioritization, workflow automation, population management, and integration into existing clinical infrastructure will become increasingly important purchasing criteria.

For device companies, the market will progressively reward ecosystems that combine reliable sensors, long wear duration, easy patient onboarding, pharmacy accessibility, broad insurance coverage, remote data sharing, algorithmic interpretation, treatment connectivity, and evidence demonstrating improvement in clinically meaningful outcomes.

By 2035, remote diabetes monitoring is expected to function less as a standalone medical-device category and more as a foundational infrastructure layer within U.S. diabetes management. Companies that control the sensing-data-clinical-action pathway will be positioned to capture a disproportionate share of the expanding USD 34 billion-plus U.S. opportunity.

 

TABLE OF CONTENT

1. U.S. Remote Diabetes Monitoring Devices Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Analytical Frameworks & Forecasting Models
1.3.6. Data Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. Continuous Glucose Monitoring Device Manufacturers
1.6.2. Connected Blood Glucose Monitoring Device Manufacturers
1.6.3. Sensor, Electronics and Contract Manufacturing Suppliers
1.6.4. Hospitals and Integrated Health Systems
1.6.5. Endocrinology and Diabetes Specialty Practices
1.6.6. Primary Care and Population Health Organizations
1.6.7. Remote Patient Monitoring and Virtual Diabetes Care Providers
1.6.8. Retail Pharmacies, Specialty Pharmacies and DME Suppliers
1.6.9. Commercial Payers, Medicare and Medicare Advantage Organizations
1.6.10. FDA, CMS and Other Regulatory Stakeholders

What this section provides: This section defines the U.S. remote diabetes monitoring devices market boundary, study scope, methodology, assumptions, technology ecosystem, and stakeholder structure so clients understand how market revenues, adoption patterns, and forecasts are measured and validated.

2. U.S. Remote Diabetes Monitoring Devices Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. U.S. Diabetes Patient Addressable Population Analysis
2.8. CGM and Connected Monitoring Adoption Snapshot
2.9. High-Growth Opportunity Areas
2.10. Key Strategic Takeaways for Market Participants

What this section provides: This section gives decision-makers a concise view of market size, growth trajectory, diabetes-monitoring penetration, major demand pockets, competitive intensity, and priority commercial opportunities through 2035.

3. U.S. Remote Diabetes Monitoring Devices Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Rising U.S. Diabetes and Prediabetes Burden
3.1.2. Rapid Expansion of Continuous Glucose Monitoring Adoption
3.1.3. Broader CGM Access Among Type 2 Diabetes Patients
3.1.4. Medicare and Commercial Insurance Coverage Expansion
3.1.5. Growth of Remote Patient Monitoring and Virtual Diabetes Care
3.1.6. Increasing Adoption of Connected and Smartphone-Enabled Devices
3.1.7. Shift Toward Value-Based Chronic Disease Management

3.2. Restraints and Their Impact Analysis
3.2.1. High Recurring Sensor and Monitoring Costs
3.2.2. Coverage Restrictions and Patient Out-of-Pocket Burden
3.2.3. Digital Access and Health-Literacy Barriers
3.2.4. Sensor Adhesion, Accuracy and User-Persistence Challenges
3.2.5. Data Overload and Clinical Workflow Burden
3.2.6. Software Reliability and Cybersecurity Risks

3.3. Opportunities and Their Impact Analysis
3.3.1. Non-Insulin-Treated Type 2 Diabetes Population
3.3.2. OTC Continuous Glucose Monitoring Expansion
3.3.3. Longer-Wear and Implantable Glucose Sensors
3.3.4. AI-Assisted Glucose Data Interpretation
3.3.5. Automated Insulin Delivery and CGM Interoperability
3.3.6. Primary Care-Based CGM Adoption
3.3.7. Rural and Underserved Diabetes Monitoring Programs
3.3.8. Multi-Parameter Remote Chronic Care Platforms

3.4. Challenges and Their Impact Analysis
3.4.1. Patient Engagement and Long-Term Adherence
3.4.2. Integration with EHR and Clinical Information Systems
3.4.3. Alert Fatigue and Clinician Capacity Constraints
3.4.4. Interoperability Across Diabetes Device Ecosystems
3.4.5. Price Competition and Reimbursement Compression

3.5. Patent & Innovation Analysis, 2021–2025
3.6. Clinical Workflow Economics Analysis
3.7. Remote Diabetes Monitoring Program Economics
3.8. Patient Acquisition, Activation and Retention Analysis
3.9. Pharmacy versus DME Fulfillment Economics
3.10. Value-Based Diabetes Management Impact Analysis

What this section provides: This section explains the clinical, commercial, reimbursement, technological, and operational forces affecting remote diabetes monitoring demand and helps clients assess both market upside and execution risks.

4. U.S. Remote Diabetes Monitoring Devices Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal

4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry

4.3. Pricing Trend Analysis, 2025–2035
4.3.1. CGM Sensor Pricing Trends
4.3.2. Connected Blood Glucose Meter Pricing Trends
4.3.3. Implantable CGM Pricing and Procedure Economics
4.3.4. OTC Glucose Monitoring Pricing Dynamics

4.4. Value Chain & Supply Chain Analysis
4.4.1. Biosensor and Raw Material Suppliers
4.4.2. Semiconductor and Electronics Suppliers
4.4.3. Device Manufacturing and Assembly
4.4.4. Software, Cloud and Connectivity Infrastructure
4.4.5. Pharmacy, DME and Direct Distribution
4.4.6. Patient Support and Remote Monitoring Services

4.5. Impact of Digitalization and Connected Diabetes Care
4.6. Application & Innovation Landscape
4.7. FDA Regulatory Framework Analysis
4.7.1. Prescription CGM Regulatory Pathways
4.7.2. Integrated CGM and Automated Insulin Delivery Requirements
4.7.3. OTC CGM Regulatory Landscape
4.7.4. Software and Connected Medical Device Oversight

4.8. CMS Reimbursement and Coverage Landscape
4.8.1. Medicare CGM Coverage
4.8.2. Remote Physiologic Monitoring Reimbursement
4.8.3. Professional CGM Reimbursement
4.8.4. Medicare Advantage Coverage Dynamics

4.9. Commercial Payer and Pharmacy Benefit Landscape
4.10. Pharmacy versus Durable Medical Equipment Channel Analysis
4.11. Import/Export Restrictions & Tariff Impact
4.12. Government Diabetes Prevention and Chronic Care Initiatives
4.13. Cybersecurity and Patient Data Privacy Environment
4.14. Payer Formulary and Coverage Decision Framework
4.15. Health System Remote Monitoring Vendor Selection Framework

What this section provides: This section provides a complete assessment of regulation, reimbursement, pricing, supply chain, payer coverage, digital integration, cybersecurity, distribution, and purchasing conditions affecting remote diabetes monitoring commercialization in the United States.

5. U.S. Remote Diabetes Monitoring Devices Market – By Product Type

5.1. Overview
5.1.1. Segment Share Analysis, By Product Type, 2025 & 2035 (%)
5.1.2. Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)

5.2. Real-Time Continuous Glucose Monitoring Systems
5.2.1. Sensors
5.2.2. Transmitters
5.2.3. Receivers and Display Devices
5.2.4. Smartphone-Connected CGM Platforms

5.3. Intermittently Scanned / Flash Glucose Monitoring Systems
5.3.1. Sensors
5.3.2. Readers
5.3.3. Smartphone-Based Scanning and Data Platforms

5.4. Implantable Continuous Glucose Monitoring Systems
5.4.1. Implantable Sensors
5.4.2. External Transmitters
5.4.3. Mobile and Cloud Monitoring Platforms

5.5. Connected Blood Glucose Monitoring Devices
5.5.1. Bluetooth-Enabled Glucose Meters
5.5.2. Cellular-Connected Glucose Meters
5.5.3. Smart Blood Glucose Monitoring Systems
5.5.4. Connected Testing Accessories

5.6. Remote Monitoring Hubs and Multi-Parameter Diabetes Devices
5.6.1. Connected Blood Pressure Monitors
5.6.2. Connected Weight Scales
5.6.3. Connected Ketone Monitoring Devices
5.6.4. Cellular and Bluetooth Monitoring Gateways
5.6.5. Other Connected Diabetes Monitoring Peripherals

What this section provides: This section identifies which remote diabetes monitoring product categories generate the largest revenue contribution and evaluates the technologies expected to gain the strongest adoption through 2035.

6. U.S. Remote Diabetes Monitoring Devices Market – By Patient Type

6.1. Overview
6.1.1. Segment Share Analysis, By Patient Type, 2025 & 2035 (%)
6.1.2. Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)

6.2. Type 1 Diabetes
6.2.1. Adults
6.2.2. Pediatric and Adolescent Patients

6.3. Insulin-Treated Type 2 Diabetes
6.3.1. Multiple Daily Injection Users
6.3.2. Basal Insulin Users
6.3.3. Insulin Pump and Automated Insulin Delivery Users

6.4. Non-Insulin-Treated Type 2 Diabetes
6.4.1. Oral Medication Users
6.4.2. GLP-1 and Other Injectable Therapy Users
6.4.3. Lifestyle-Managed Type 2 Diabetes

6.5. Gestational Diabetes and High-Risk Pregnancy
6.5.1. Insulin-Treated Gestational Diabetes
6.5.2. Non-Insulin-Treated Gestational Diabetes
6.5.3. Pre-Existing Diabetes in Pregnancy

6.6. Prediabetes and High-Risk Metabolic Populations
6.6.1. Diagnosed Prediabetes
6.6.2. Obesity and Metabolic Risk Populations
6.6.3. Consumer Metabolic Monitoring Users

What this section provides: This section quantifies the addressable market by diabetes and metabolic-risk population and identifies the patient groups expected to create the largest incremental monitoring opportunity through 2035.

7. U.S. Remote Diabetes Monitoring Devices Market – By Monitoring Model

7.1. Overview
7.1.1. Segment Share Analysis, By Monitoring Model, 2025 & 2035 (%)
7.1.2. Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)

7.2. Clinician-Prescribed Continuous Remote Monitoring
7.2.1. Specialist-Led Monitoring
7.2.2. Primary Care-Led Monitoring
7.2.3. Integrated Health System Monitoring

7.3. Patient-Managed Monitoring with Cloud Sharing
7.3.1. Clinician Data Sharing
7.3.2. Caregiver and Family Data Sharing
7.3.3. Automated Alert and Notification Models

7.4. Structured Remote Patient Monitoring Programs
7.4.1. Health System RPM Programs
7.4.2. Physician Practice RPM Programs
7.4.3. Virtual Diabetes Care Programs
7.4.4. Payer-Sponsored RPM Programs

7.5. Professional and Episodic Glucose Monitoring
7.5.1. Diagnostic Professional CGM
7.5.2. Therapy Optimization Monitoring
7.5.3. Short-Term Lifestyle and Behavioral Monitoring

7.6. OTC and Direct-to-Consumer Monitoring
7.6.1. OTC Diabetes Glucose Monitoring
7.6.2. Consumer Metabolic Health Monitoring
7.6.3. Employer and Wellness-Based Monitoring

What this section provides: This section evaluates how diabetes-monitoring devices are deployed, supervised, and consumed, helping clients identify growth differences between prescription, RPM, professional, self-managed, and OTC monitoring models.

8. U.S. Remote Diabetes Monitoring Devices Market – By End User

8.1. Overview
8.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
8.1.2. Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

8.2. Hospitals and Integrated Health Systems
8.2.1. Academic Medical Centers
8.2.2. Community Hospital Networks
8.2.3. Integrated Delivery Networks
8.2.4. Population Health Programs

8.3. Endocrinology and Diabetes Specialty Practices
8.3.1. Independent Endocrinology Practices
8.3.2. Hospital-Affiliated Diabetes Centers
8.3.3. Diabetes Education and Management Centers

8.4. Primary Care Practices
8.4.1. Independent Primary Care Groups
8.4.2. Multispecialty Physician Groups
8.4.3. Value-Based Primary Care Organizations

8.5. Home Healthcare and Remote Monitoring Providers
8.5.1. Home Health Agencies
8.5.2. Remote Patient Monitoring Companies
8.5.3. Virtual Diabetes Care Providers
8.5.4. Chronic Care Management Organizations

8.6. Pharmacies, Retail Health and Direct-to-Consumer Channels
8.6.1. Retail Pharmacies
8.6.2. Specialty Pharmacies
8.6.3. Durable Medical Equipment Suppliers
8.6.4. Online and Direct-to-Consumer Channels
8.6.5. Employer and Health Plan Distribution Programs

What this section provides: This section identifies the provider, retail, home-care, and digital-health customer groups driving device prescriptions, procurement, patient enrollment, monitoring utilization, and recurring sensor demand.

9. U.S. Remote Diabetes Monitoring Devices Market – By Geography

9.1. Introduction
9.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
9.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
9.1.3. Regional Diabetes Prevalence and Addressable Patient Analysis
9.1.4. Regional CGM and Connected Monitoring Adoption Analysis
9.1.5. Regional Medicare and Commercial Payer Coverage Dynamics
9.1.6. Regional Endocrinology Access and Remote Care Infrastructure
9.1.7. Regional Pharmacy, DME and Distribution Dynamics

9.2. West Region

9.2.1. Regional Overview & Trends
9.2.2. West Region Diabetes Burden and Addressable Population
9.2.3. West Region Key Manufacturers, Providers and Distribution Ecosystem
9.2.4. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.2.5. West Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.6. West Region Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.2.7. West Region Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.2.8. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.2.9. California

9.2.9.1. Overview
9.2.9.2. California Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.9.3. California Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.2.9.4. California Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.2.9.5. California Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.2.10. Washington

9.2.10.1. Overview
9.2.10.2. Washington Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.10.3. Washington Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.2.10.4. Washington Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.2.10.5. Washington Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.2.11. Arizona

9.2.11.1. Overview
9.2.11.2. Arizona Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.11.3. Arizona Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.2.11.4. Arizona Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.2.11.5. Arizona Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.2.12. Colorado

9.2.12.1. Overview
9.2.12.2. Colorado Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.12.3. Colorado Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.2.12.4. Colorado Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.2.12.5. Colorado Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.2.13. Oregon

9.2.13.1. Overview
9.2.13.2. Oregon Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.13.3. Oregon Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.2.13.4. Oregon Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.2.13.5. Oregon Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.2.14. Utah

9.2.14.1. Overview
9.2.14.2. Utah Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.14.3. Utah Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.2.14.4. Utah Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.2.14.5. Utah Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.2.15. Nevada

9.2.15.1. Overview
9.2.15.2. Nevada Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.15.3. Nevada Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.2.15.4. Nevada Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.2.15.5. Nevada Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.2.16. New Mexico

9.2.16.1. Overview
9.2.16.2. New Mexico Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.16.3. New Mexico Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.2.16.4. New Mexico Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.2.16.5. New Mexico Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.2.17. Idaho

9.2.17.1. Overview
9.2.17.2. Idaho Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.17.3. Idaho Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.2.17.4. Idaho Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.2.17.5. Idaho Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.2.18. Montana

9.2.18.1. Overview
9.2.18.2. Montana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.18.3. Montana Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.2.18.4. Montana Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.2.18.5. Montana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.2.19. Wyoming

9.2.19.1. Overview
9.2.19.2. Wyoming Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.19.3. Wyoming Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.2.19.4. Wyoming Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.2.19.5. Wyoming Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.2.20. Alaska

9.2.20.1. Overview
9.2.20.2. Alaska Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.20.3. Alaska Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.2.20.4. Alaska Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.2.20.5. Alaska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.2.21. Hawaii

9.2.21.1. Overview
9.2.21.2. Hawaii Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.21.3. Hawaii Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.2.21.4. Hawaii Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.2.21.5. Hawaii Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.3. Northeast Region

9.3.1. Regional Overview & Trends
9.3.2. Northeast Region Diabetes Burden and Addressable Population
9.3.3. Northeast Region Key Manufacturers, Providers and Distribution Ecosystem
9.3.4. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.3.5. Northeast Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.6. Northeast Region Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.3.7. Northeast Region Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.3.8. Northeast Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.3.9. New York

9.3.9.1. Overview
9.3.9.2. New York Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.9.3. New York Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.3.9.4. New York Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.3.9.5. New York Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.3.10. Massachusetts

9.3.10.1. Overview
9.3.10.2. Massachusetts Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.10.3. Massachusetts Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.3.10.4. Massachusetts Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.3.10.5. Massachusetts Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.3.11. New Jersey

9.3.11.1. Overview
9.3.11.2. New Jersey Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.11.3. New Jersey Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.3.11.4. New Jersey Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.3.11.5. New Jersey Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.3.12. Pennsylvania

9.3.12.1. Overview
9.3.12.2. Pennsylvania Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.12.3. Pennsylvania Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.3.12.4. Pennsylvania Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.3.12.5. Pennsylvania Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.3.13. Connecticut

9.3.13.1. Overview
9.3.13.2. Connecticut Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.13.3. Connecticut Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.3.13.4. Connecticut Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.3.13.5. Connecticut Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.3.14. Maine

9.3.14.1. Overview
9.3.14.2. Maine Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.14.3. Maine Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.3.14.4. Maine Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.3.14.5. Maine Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.3.15. Vermont

9.3.15.1. Overview
9.3.15.2. Vermont Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.15.3. Vermont Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.3.15.4. Vermont Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.3.15.5. Vermont Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.3.16. New Hampshire

9.3.16.1. Overview
9.3.16.2. New Hampshire Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.16.3. New Hampshire Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.3.16.4. New Hampshire Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.3.16.5. New Hampshire Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.3.17. Rhode Island

9.3.17.1. Overview
9.3.17.2. Rhode Island Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.17.3. Rhode Island Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.3.17.4. Rhode Island Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.3.17.5. Rhode Island Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.3.18. Delaware

9.3.18.1. Overview
9.3.18.2. Delaware Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.18.3. Delaware Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.3.18.4. Delaware Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.3.18.5. Delaware Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4. South Region

9.4.1. Regional Overview & Trends
9.4.2. South Region Diabetes Burden and Addressable Population
9.4.3. South Region Key Manufacturers, Providers and Distribution Ecosystem
9.4.4. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.4.5. South Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.6. South Region Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.4.7. South Region Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.4.8. South Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.9. Texas

9.4.9.1. Overview
9.4.9.2. Texas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.9.3. Texas Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.4.9.4. Texas Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.4.9.5. Texas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.10. Florida

9.4.10.1. Overview
9.4.10.2. Florida Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.10.3. Florida Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.4.10.4. Florida Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.4.10.5. Florida Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.11. Georgia

9.4.11.1. Overview
9.4.11.2. Georgia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.11.3. Georgia Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.4.11.4. Georgia Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.4.11.5. Georgia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.12. North Carolina

9.4.12.1. Overview
9.4.12.2. North Carolina Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.12.3. North Carolina Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.4.12.4. North Carolina Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.4.12.5. North Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.13. Tennessee

9.4.13.1. Overview
9.4.13.2. Tennessee Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.13.3. Tennessee Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.4.13.4. Tennessee Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.4.13.5. Tennessee Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.14. South Carolina

9.4.14.1. Overview
9.4.14.2. South Carolina Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.14.3. South Carolina Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.4.14.4. South Carolina Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.4.14.5. South Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.15. Alabama

9.4.15.1. Overview
9.4.15.2. Alabama Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.15.3. Alabama Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.4.15.4. Alabama Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.4.15.5. Alabama Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.16. Mississippi

9.4.16.1. Overview
9.4.16.2. Mississippi Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.16.3. Mississippi Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.4.16.4. Mississippi Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.4.16.5. Mississippi Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.17. Louisiana

9.4.17.1. Overview
9.4.17.2. Louisiana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.17.3. Louisiana Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.4.17.4. Louisiana Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.4.17.5. Louisiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.18. Arkansas

9.4.18.1. Overview
9.4.18.2. Arkansas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.18.3. Arkansas Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.4.18.4. Arkansas Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.4.18.5. Arkansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.19. Kentucky

9.4.19.1. Overview
9.4.19.2. Kentucky Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.19.3. Kentucky Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.4.19.4. Kentucky Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.4.19.5. Kentucky Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.20. Oklahoma

9.4.20.1. Overview
9.4.20.2. Oklahoma Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.20.3. Oklahoma Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.4.20.4. Oklahoma Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.4.20.5. Oklahoma Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.21. Virginia

9.4.21.1. Overview
9.4.21.2. Virginia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.21.3. Virginia Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.4.21.4. Virginia Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.4.21.5. Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.22. Maryland

9.4.22.1. Overview
9.4.22.2. Maryland Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.22.3. Maryland Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.4.22.4. Maryland Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.4.22.5. Maryland Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.23. West Virginia

9.4.23.1. Overview
9.4.23.2. West Virginia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.23.3. West Virginia Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.4.23.4. West Virginia Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.4.23.5. West Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.5. Midwest Region

9.5.1. Regional Overview & Trends
9.5.2. Midwest Region Diabetes Burden and Addressable Population
9.5.3. Midwest Region Key Manufacturers, Providers and Distribution Ecosystem
9.5.4. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.5.5. Midwest Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.6. Midwest Region Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.5.7. Midwest Region Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.5.8. Midwest Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.5.9. Illinois

9.5.9.1. Overview
9.5.9.2. Illinois Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.9.3. Illinois Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.5.9.4. Illinois Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.5.9.5. Illinois Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.5.10. Ohio

9.5.10.1. Overview
9.5.10.2. Ohio Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.10.3. Ohio Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.5.10.4. Ohio Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.5.10.5. Ohio Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.5.11. Michigan

9.5.11.1. Overview
9.5.11.2. Michigan Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.11.3. Michigan Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.5.11.4. Michigan Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.5.11.5. Michigan Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.5.12. Minnesota

9.5.12.1. Overview
9.5.12.2. Minnesota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.12.3. Minnesota Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.5.12.4. Minnesota Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.5.12.5. Minnesota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.5.13. Indiana

9.5.13.1. Overview
9.5.13.2. Indiana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.13.3. Indiana Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.5.13.4. Indiana Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.5.13.5. Indiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.5.14. Wisconsin

9.5.14.1. Overview
9.5.14.2. Wisconsin Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.14.3. Wisconsin Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.5.14.4. Wisconsin Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.5.14.5. Wisconsin Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.5.15. Missouri

9.5.15.1. Overview
9.5.15.2. Missouri Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.15.3. Missouri Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.5.15.4. Missouri Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.5.15.5. Missouri Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.5.16. Iowa

9.5.16.1. Overview
9.5.16.2. Iowa Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.16.3. Iowa Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.5.16.4. Iowa Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.5.16.5. Iowa Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.5.17. Kansas

9.5.17.1. Overview
9.5.17.2. Kansas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.17.3. Kansas Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.5.17.4. Kansas Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.5.17.5. Kansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.5.18. Nebraska

9.5.18.1. Overview
9.5.18.2. Nebraska Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.18.3. Nebraska Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.5.18.4. Nebraska Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.5.18.5. Nebraska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.5.19. North Dakota

9.5.19.1. Overview
9.5.19.2. North Dakota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.19.3. North Dakota Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.5.19.4. North Dakota Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.5.19.5. North Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.5.20. South Dakota

9.5.20.1. Overview
9.5.20.2. South Dakota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.20.3. South Dakota Market Size and Forecast, By Patient Type, 2021–2035 (US$ Billion)
9.5.20.4. South Dakota Market Size and Forecast, By Monitoring Model, 2021–2035 (US$ Billion)
9.5.20.5. South Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

What this section provides: This section delivers detailed regional and state-level analysis across all 50 U.S. states, allowing clients to identify diabetes-burden hotspots, high-value CGM markets, remote-care opportunities, payer-access differences, rural monitoring needs, and state-level commercial expansion priorities.

10. U.S. Remote Diabetes Monitoring Devices Market: Competitive Landscape & Company Profiles

10.1. Market Share Analysis, 2025
10.2. Competitive Benchmarking Analysis
10.2.1. CGM Installed Patient Base
10.2.2. Sensor Wear Duration
10.2.3. Pricing and Reimbursement Access
10.2.4. Pharmacy and DME Availability
10.2.5. Automated Insulin Delivery Interoperability
10.2.6. Clinician Data Management Capabilities
10.2.7. OTC and Consumer Market Positioning

10.3. Company Positioning Matrix
10.3.1. Leaders
10.3.2. Challengers
10.3.3. Innovators
10.3.4. Emerging Players

10.4. Company Profiles

10.4.1. Abbott Laboratories
10.4.2. Dexcom, Inc.
10.4.3. Medtronic plc
10.4.4. Senseonics Holdings, Inc.
10.4.5. Ascensia Diabetes Care
10.4.6. Roche Diabetes Care
10.4.7. LifeScan
10.4.8. Tandem Diabetes Care, Inc.
10.4.9. Insulet Corporation
10.4.10. Beta Bionics, Inc.
10.4.11. Sequel Med Tech
10.4.12. DarioHealth Corp.
10.4.13. Glooko, Inc.
10.4.14. Teladoc Health / Livongo
10.4.15. iHealth Labs Inc.
10.4.16. AgaMatrix, Inc.
10.4.17. Trividia Health, Inc.
10.4.18. Nova Biomedical
10.4.19. embecta Corp.
10.4.20. Withings
10.4.21. Omada Health
10.4.22. Welldoc, Inc.
10.4.23. Validic
10.4.24. One Drop
10.4.25. Smart Meter LLC

10.5. Competitive Strategies
10.5.1. Product Launch and Sensor Innovation Strategy
10.5.2. Pharmacy Access Expansion
10.5.3. Payer Contracting Strategy
10.5.4. Automated Insulin Delivery Partnerships
10.5.5. Digital Health and Remote Monitoring Partnerships
10.5.6. Primary Care Market Expansion
10.5.7. OTC and Consumer Market Entry

10.6. Mergers, Acquisitions and Strategic Investments
10.7. Partnerships and Technology Integrations
10.8. FDA Clearances and Regulatory Milestones
10.9. Recent Competitive Developments

Note: Each company profile will include company overview, U.S. remote diabetes monitoring portfolio, product and technology positioning, commercial strategy, financial positioning where available, reimbursement access, partnerships, regulatory updates, innovation pipeline, and recent developments.

What this section provides: This section provides competitor benchmarking, market-share visibility, device and platform positioning, interoperability strategies, regulatory intelligence, payer-access assessment, and strategic analysis of the leading remote diabetes monitoring companies operating in the United States.

11. U.S. Remote Diabetes Monitoring Devices Market: Future Market Outlook, 2026–2035

11.1. Scenario Analysis
11.1.1. Optimistic Scenario
11.1.2. Realistic Scenario
11.1.3. Pessimistic Scenario

11.2. Disruptive Technologies Impact
11.2.1. Longer-Wear CGM Sensors
11.2.2. Implantable Annual-Wear CGM
11.2.3. OTC Continuous Glucose Monitoring
11.2.4. AI-Assisted Glucose Interpretation
11.2.5. Predictive Hypoglycemia and Hyperglycemia Analytics
11.2.6. Automated Insulin Delivery Integration
11.2.7. Multi-Analyte and Next-Generation Biosensors
11.2.8. Smartphone-Only and Receiver-Free Monitoring
11.2.9. Digital Twin and Personalized Diabetes Management

11.3. Future Reimbursement and Coverage Scenarios
11.4. Evolution of CGM Adoption Beyond Insulin Users
11.5. Primary Care and Population Health Adoption Outlook
11.6. OTC and Consumer Glucose Monitoring Outlook
11.7. Rural Diabetes Monitoring Opportunity
11.8. Emerging Business Models
11.9. Business Opportunities for Startups and Existing Players
11.10. Investment Prioritization Matrix
11.11. Market White-Space Analysis

What this section provides: This section prepares clients for technology disruption, coverage expansion, patient-base broadening, emerging business models, new competitive threats, and investment opportunities expected to reshape remote diabetes monitoring through 2035.

12. U.S. Remote Diabetes Monitoring Devices Market: Strategic Recommendations

12.1. Recommendations for CGM and Connected Device Manufacturers
12.2. Recommendations for Hospitals and Integrated Health Systems
12.3. Recommendations for Endocrinology Practices
12.4. Recommendations for Primary Care Organizations
12.5. Recommendations for Payers and Medicare Advantage Organizations
12.6. Recommendations for Pharmacies and DME Suppliers
12.7. Recommendations for Remote Patient Monitoring Providers
12.8. Recommendations for Digital Diabetes Care Companies
12.9. Recommendations for Investors and Private Equity Firms
12.10. Recommendations for New Entrants and Startups
12.11. Go-to-Market Strategy Considerations
12.12. Product Positioning and Portfolio Expansion Guidance
12.13. Reimbursement and Market Access Strategy
12.14. State-Level Market Entry Prioritization
12.15. Partnership and Ecosystem Strategy

What this section provides: This section converts market intelligence into actionable recommendations covering market entry, reimbursement, product development, channel expansion, state prioritization, payer engagement, partnerships, portfolio strategy, and competitive differentiation.

13. U.S. Remote Diabetes Monitoring Devices Market: Disclaimer

13.1. Scope Limitation
13.2. Data Use Limitation
13.3. Market Definition Limitation
13.4. Forecasting Limitation
13.5. Patient Population Estimation Limitation
13.6. Regulatory and Reimbursement Limitation
13.7. Company and Competitive Intelligence Limitation
13.8. Legal Disclaimer
13.9. Third-Party Data Disclaimer

What this section provides: This section clarifies the report’s scope limitations, market-estimation boundaries, forecast assumptions, regulatory and reimbursement uncertainties, data-use conditions, third-party information limitations, and legal terms.

 

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. Remote Diabetes Monitoring Devices Market: Market Definition and Scope
TABLE 3: U.S. Remote Diabetes Monitoring Devices Market: Research Methodology Framework
TABLE 4: U.S. Remote Diabetes Monitoring Devices Market: Key Assumptions
TABLE 5: U.S. Remote Diabetes Monitoring Devices Market: Market Ecosystem Overview
TABLE 6: U.S. Remote Diabetes Monitoring Devices Market: Stakeholder Analysis
TABLE 7: U.S. Remote Diabetes Monitoring Devices Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. Remote Diabetes Monitoring Devices Market: Analyst Viewpoint Summary
TABLE 9: U.S. Remote Diabetes Monitoring Devices Market: Market Attractiveness Index
TABLE 10: U.S. Remote Diabetes Monitoring Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. Remote Diabetes Monitoring Devices Market: Base Year Market Positioning, 2025
TABLE 12: U.S. Remote Diabetes Monitoring Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 13: U.S. Remote Diabetes Monitoring Devices Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 14: U.S. Remote Diabetes Monitoring Devices Market: Addressable Diabetes Population and High-Growth Opportunity Areas
TABLE 15: U.S. Remote Diabetes Monitoring Devices Market: Drivers; Impact Analysis
TABLE 16: U.S. Remote Diabetes Monitoring Devices Market: Restraints; Impact Analysis
TABLE 17: U.S. Remote Diabetes Monitoring Devices Market: Opportunities; Impact Analysis
TABLE 18: U.S. Remote Diabetes Monitoring Devices Market: Challenges; Impact Analysis
TABLE 19: U.S. Remote Diabetes Monitoring Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 20: U.S. Remote Diabetes Monitoring Devices Market: Clinical Workflow Economics Matrix
TABLE 21: U.S. Remote Diabetes Monitoring Devices Market: Remote Diabetes Monitoring Program Economics
TABLE 22: U.S. Remote Diabetes Monitoring Devices Market: Patient Acquisition, Activation and Retention Analysis
TABLE 23: U.S. Remote Diabetes Monitoring Devices Market: Pharmacy versus DME Fulfillment Economics
TABLE 24: U.S. Remote Diabetes Monitoring Devices Market: Value-Based Diabetes Management Impact Analysis
TABLE 25: U.S. Remote Diabetes Monitoring Devices Market: PESTEL Analysis
TABLE 26: U.S. Remote Diabetes Monitoring Devices Market: Porter’s Five Forces Analysis
TABLE 27: U.S. Remote Diabetes Monitoring Devices Market: Pricing Trend Analysis, 2025–2035
TABLE 28: U.S. Remote Diabetes Monitoring Devices Market: Value Chain Analysis
TABLE 29: U.S. Remote Diabetes Monitoring Devices Market: Supply Chain Analysis
TABLE 30: U.S. Remote Diabetes Monitoring Devices Market: Digitalization and Connected Diabetes Care Impact
TABLE 31: U.S. Remote Diabetes Monitoring Devices Market: Application & Innovation Landscape
TABLE 32: U.S. Remote Diabetes Monitoring Devices Market: FDA Regulatory Framework Analysis
TABLE 33: U.S. Remote Diabetes Monitoring Devices Market: CMS Reimbursement and Coverage Landscape
TABLE 34: U.S. Remote Diabetes Monitoring Devices Market: Commercial Payer and Pharmacy Benefit Landscape
TABLE 35: U.S. Remote Diabetes Monitoring Devices Market: Pharmacy versus Durable Medical Equipment Channel Analysis
TABLE 36: U.S. Remote Diabetes Monitoring Devices Market: Import/Export Restrictions & Tariff Impact
TABLE 37: U.S. Remote Diabetes Monitoring Devices Market: Government Diabetes and Chronic Care Initiatives
TABLE 38: U.S. Remote Diabetes Monitoring Devices Market: Cybersecurity and Patient Data Privacy Environment
TABLE 39: U.S. Remote Diabetes Monitoring Devices Market: Health System Remote Monitoring Vendor Selection Framework
TABLE 40: U.S. Remote Diabetes Monitoring Devices Market: Product Type Snapshot, 2025
TABLE 41: Segment Dashboard; Definition and Scope, by Product Type
TABLE 42: U.S. Remote Diabetes Monitoring Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 43: U.S. Remote Diabetes Monitoring Devices Market: Segment Share Analysis, by Product Type, 2025 & 2035 (%)
TABLE 44: U.S. Remote Diabetes Monitoring Devices Market: Real-Time Continuous Glucose Monitoring Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 45: U.S. Remote Diabetes Monitoring Devices Market: Intermittently Scanned / Flash Glucose Monitoring Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 46: U.S. Remote Diabetes Monitoring Devices Market: Implantable Continuous Glucose Monitoring Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 47: U.S. Remote Diabetes Monitoring Devices Market: Connected Blood Glucose Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 48: U.S. Remote Diabetes Monitoring Devices Market: Remote Monitoring Hubs and Multi-Parameter Diabetes Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 49: U.S. Remote Diabetes Monitoring Devices Market: Patient Type Snapshot, 2025
TABLE 50: Segment Dashboard; Definition and Scope, by Patient Type
TABLE 51: U.S. Remote Diabetes Monitoring Devices Market, by Patient Type, 2021–2035 (US$ Billion)
TABLE 52: U.S. Remote Diabetes Monitoring Devices Market: Segment Share Analysis, by Patient Type, 2025 & 2035 (%)
TABLE 53: U.S. Remote Diabetes Monitoring Devices Market: Type 1 Diabetes Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 54: U.S. Remote Diabetes Monitoring Devices Market: Insulin-Treated Type 2 Diabetes Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 55: U.S. Remote Diabetes Monitoring Devices Market: Non-Insulin-Treated Type 2 Diabetes Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 56: U.S. Remote Diabetes Monitoring Devices Market: Gestational Diabetes and High-Risk Pregnancy Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 57: U.S. Remote Diabetes Monitoring Devices Market: Prediabetes and High-Risk Metabolic Populations Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 58: U.S. Remote Diabetes Monitoring Devices Market: Monitoring Model Snapshot, 2025
TABLE 59: Segment Dashboard; Definition and Scope, by Monitoring Model
TABLE 60: U.S. Remote Diabetes Monitoring Devices Market, by Monitoring Model, 2021–2035 (US$ Billion)
TABLE 61: U.S. Remote Diabetes Monitoring Devices Market: Segment Share Analysis, by Monitoring Model, 2025 & 2035 (%)
TABLE 62: U.S. Remote Diabetes Monitoring Devices Market: Clinician-Prescribed Continuous Remote Monitoring Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 63: U.S. Remote Diabetes Monitoring Devices Market: Patient-Managed Monitoring with Cloud Sharing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 64: U.S. Remote Diabetes Monitoring Devices Market: Structured Remote Patient Monitoring Programs Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 65: U.S. Remote Diabetes Monitoring Devices Market: Professional and Episodic Glucose Monitoring Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 66: U.S. Remote Diabetes Monitoring Devices Market: OTC and Direct-to-Consumer Monitoring Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 67: U.S. Remote Diabetes Monitoring Devices Market: End User Snapshot, 2025
TABLE 68: Segment Dashboard; Definition and Scope, by End User
TABLE 69: U.S. Remote Diabetes Monitoring Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 70: U.S. Remote Diabetes Monitoring Devices Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 71: U.S. Remote Diabetes Monitoring Devices Market: Hospitals and Integrated Health Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 72: U.S. Remote Diabetes Monitoring Devices Market: Endocrinology and Diabetes Specialty Practices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 73: U.S. Remote Diabetes Monitoring Devices Market: Primary Care Practices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 74: U.S. Remote Diabetes Monitoring Devices Market: Home Healthcare and Remote Monitoring Providers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 75: U.S. Remote Diabetes Monitoring Devices Market: Pharmacies, Retail Health and Direct-to-Consumer Channels Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 76: U.S. Remote Diabetes Monitoring Devices Market: Regional Snapshot, 2025
TABLE 77: Segment Dashboard; Definition and Scope, by Region
TABLE 78: U.S. Remote Diabetes Monitoring Devices Market, by Region, 2021–2035 (US$ Billion)
TABLE 79: U.S. Remote Diabetes Monitoring Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 80: West Region U.S. Remote Diabetes Monitoring Devices Market: Regional Overview and Trends
TABLE 81: West Region U.S. Remote Diabetes Monitoring Devices Market: Key Manufacturers, Providers and Distribution Ecosystem
TABLE 82: West Region U.S. Remote Diabetes Monitoring Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 83: West Region U.S. Remote Diabetes Monitoring Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 84: West Region U.S. Remote Diabetes Monitoring Devices Market, by Patient Type, 2021–2035 (US$ Billion)
TABLE 85: West Region U.S. Remote Diabetes Monitoring Devices Market, by Monitoring Model, 2021–2035 (US$ Billion)
TABLE 86: West Region U.S. Remote Diabetes Monitoring Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 87: California Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 88: Washington Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 89: Arizona Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 90: Colorado Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 91: Oregon Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 92: Utah Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 93: Nevada Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 94: New Mexico Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 95: Idaho Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 96: Montana Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 97: Wyoming Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 98: Alaska Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 99: Hawaii Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 100: Northeast Region U.S. Remote Diabetes Monitoring Devices Market: Regional Overview and Trends
TABLE 101: Northeast Region U.S. Remote Diabetes Monitoring Devices Market: Key Manufacturers, Providers and Distribution Ecosystem
TABLE 102: Northeast Region U.S. Remote Diabetes Monitoring Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 103: Northeast Region U.S. Remote Diabetes Monitoring Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 104: Northeast Region U.S. Remote Diabetes Monitoring Devices Market, by Patient Type, 2021–2035 (US$ Billion)
TABLE 105: Northeast Region U.S. Remote Diabetes Monitoring Devices Market, by Monitoring Model, 2021–2035 (US$ Billion)
TABLE 106: Northeast Region U.S. Remote Diabetes Monitoring Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 107: New York Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 108: Massachusetts Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 109: New Jersey Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 110: Pennsylvania Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 111: Connecticut Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 112: Maine Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 113: Vermont Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 114: New Hampshire Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 115: Rhode Island Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 116: Delaware Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 117: South Region U.S. Remote Diabetes Monitoring Devices Market: Regional Overview and Trends
TABLE 118: South Region U.S. Remote Diabetes Monitoring Devices Market: Key Manufacturers, Providers and Distribution Ecosystem
TABLE 119: South Region U.S. Remote Diabetes Monitoring Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 120: South Region U.S. Remote Diabetes Monitoring Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 121: South Region U.S. Remote Diabetes Monitoring Devices Market, by Patient Type, 2021–2035 (US$ Billion)
TABLE 122: South Region U.S. Remote Diabetes Monitoring Devices Market, by Monitoring Model, 2021–2035 (US$ Billion)
TABLE 123: South Region U.S. Remote Diabetes Monitoring Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 124: Texas Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 125: Florida Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 126: Georgia Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 127: North Carolina Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 128: Tennessee Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 129: South Carolina Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 130: Alabama Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 131: Mississippi Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 132: Louisiana Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 133: Arkansas Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 134: Kentucky Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 135: Oklahoma Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 136: Virginia Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 137: Maryland Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 138: West Virginia Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 139: Midwest Region U.S. Remote Diabetes Monitoring Devices Market: Regional Overview and Trends
TABLE 140: Midwest Region U.S. Remote Diabetes Monitoring Devices Market: Key Manufacturers, Providers and Distribution Ecosystem
TABLE 141: Midwest Region U.S. Remote Diabetes Monitoring Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 142: Midwest Region U.S. Remote Diabetes Monitoring Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 143: Midwest Region U.S. Remote Diabetes Monitoring Devices Market, by Patient Type, 2021–2035 (US$ Billion)
TABLE 144: Midwest Region U.S. Remote Diabetes Monitoring Devices Market, by Monitoring Model, 2021–2035 (US$ Billion)
TABLE 145: Midwest Region U.S. Remote Diabetes Monitoring Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 146: Illinois Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 147: Ohio Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 148: Michigan Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 149: Minnesota Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 150: Indiana Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 151: Wisconsin Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 152: Missouri Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 153: Iowa Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 154: Kansas Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 155: Nebraska Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 156: North Dakota Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 157: South Dakota Remote Diabetes Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 158: U.S. Remote Diabetes Monitoring Devices Market: Competitive Landscape Snapshot, 2025
TABLE 159: U.S. Remote Diabetes Monitoring Devices Market: Key Company Market Share Analysis, 2025
TABLE 160: U.S. Remote Diabetes Monitoring Devices Market: Competitive Benchmarking Matrix
TABLE 161: U.S. Remote Diabetes Monitoring Devices Market: Company Positioning Matrix
TABLE 162: U.S. Remote Diabetes Monitoring Devices Market: Product and Platform Portfolio Benchmarking
TABLE 163: U.S. Remote Diabetes Monitoring Devices Market: Strategic Developments, Partnerships, M&A and Product Launches
TABLE 164: Abbott Laboratories: Company Profile
TABLE 165: Dexcom, Inc.: Company Profile
TABLE 166: Medtronic plc: Company Profile
TABLE 167: Senseonics Holdings, Inc.: Company Profile
TABLE 168: Ascensia Diabetes Care: Company Profile
TABLE 169: Roche Diabetes Care: Company Profile
TABLE 170: LifeScan: Company Profile
TABLE 171: Tandem Diabetes Care, Inc.: Company Profile
TABLE 172: Insulet Corporation: Company Profile
TABLE 173: Beta Bionics, Inc.: Company Profile
TABLE 174: Sequel Med Tech: Company Profile
TABLE 175: DarioHealth Corp.: Company Profile
TABLE 176: Glooko, Inc.: Company Profile
TABLE 177: Teladoc Health / Livongo: Company Profile
TABLE 178: iHealth Labs Inc.: Company Profile
TABLE 179: AgaMatrix, Inc.: Company Profile
TABLE 180: Trividia Health, Inc.: Company Profile
TABLE 181: Nova Biomedical: Company Profile
TABLE 182: embecta Corp.: Company Profile
TABLE 183: Withings: Company Profile
TABLE 184: Omada Health: Company Profile
TABLE 185: Welldoc, Inc.: Company Profile
TABLE 186: Validic: Company Profile
TABLE 187: One Drop: Company Profile
TABLE 188: Smart Meter LLC: Company Profile
TABLE 189: U.S. Remote Diabetes Monitoring Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 190: U.S. Remote Diabetes Monitoring Devices Market: Disruptive Technologies Impact Matrix
TABLE 191: U.S. Remote Diabetes Monitoring Devices Market: Future Reimbursement and Coverage Scenarios
TABLE 192: U.S. Remote Diabetes Monitoring Devices Market: CGM Adoption Beyond Insulin Users Outlook
TABLE 193: U.S. Remote Diabetes Monitoring Devices Market: OTC and Consumer Monitoring Outlook
TABLE 194: U.S. Remote Diabetes Monitoring Devices Market: Emerging Business Trends
TABLE 195: U.S. Remote Diabetes Monitoring Devices Market: Business Opportunities for Startups and Existing Players
TABLE 196: U.S. Remote Diabetes Monitoring Devices Market: Investment Prioritization Matrix
TABLE 197: U.S. Remote Diabetes Monitoring Devices Market: Market White-Space Analysis
TABLE 198: U.S. Remote Diabetes Monitoring Devices Market: Strategic Recommendations for CGM and Connected Device Manufacturers
TABLE 199: U.S. Remote Diabetes Monitoring Devices Market: Strategic Recommendations for Hospitals and Integrated Health Systems
TABLE 200: U.S. Remote Diabetes Monitoring Devices Market: Strategic Recommendations for Endocrinology and Primary Care Organizations
TABLE 201: U.S. Remote Diabetes Monitoring Devices Market: Strategic Recommendations for Payers and Medicare Advantage Organizations
TABLE 202: U.S. Remote Diabetes Monitoring Devices Market: Strategic Recommendations for Pharmacies and DME Suppliers
TABLE 203: U.S. Remote Diabetes Monitoring Devices Market: Strategic Recommendations for Remote Patient Monitoring Providers
TABLE 204: U.S. Remote Diabetes Monitoring Devices Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 205: U.S. Remote Diabetes Monitoring Devices Market: Strategic Recommendations for New Entrants and Startups
TABLE 206: U.S. Remote Diabetes Monitoring Devices Market: Go-to-Market Strategy Considerations
TABLE 207: U.S. Remote Diabetes Monitoring Devices Market: Product Positioning and Portfolio Expansion Guidance
TABLE 208: U.S. Remote Diabetes Monitoring Devices Market: Reimbursement and Market Access Strategy
TABLE 209: U.S. Remote Diabetes Monitoring Devices Market: State-Level Market Entry Prioritization
TABLE 210: U.S. Remote Diabetes Monitoring Devices Market: Partnership and Ecosystem Strategy
TABLE 211: U.S. Remote Diabetes Monitoring Devices Market: Scope Limitation
TABLE 212: U.S. Remote Diabetes Monitoring Devices Market: Data Use Limitation
TABLE 213: U.S. Remote Diabetes Monitoring Devices Market: Market Definition Limitation
TABLE 214: U.S. Remote Diabetes Monitoring Devices Market: Forecasting Limitation
TABLE 215: U.S. Remote Diabetes Monitoring Devices Market: Patient Population Estimation Limitation
TABLE 216: U.S. Remote Diabetes Monitoring Devices Market: Regulatory and Reimbursement Limitation
TABLE 217: U.S. Remote Diabetes Monitoring Devices Market: Company and Competitive Intelligence Limitation
TABLE 218: U.S. Remote Diabetes Monitoring Devices Market: Legal Disclaimer
TABLE 219: U.S. Remote Diabetes Monitoring Devices Market: Third-Party Data Disclaimer

List of Figures

FIGURE 1: U.S. Remote Diabetes Monitoring Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: Market Ecosystem and Stakeholder Framework
FIGURE 4: Value Chain Analysis
FIGURE 5: Supply Chain Analysis
FIGURE 6: PESTEL Analysis
FIGURE 7: Porter’s Five Forces Analysis
FIGURE 8: Market Attractiveness Analysis
FIGURE 9: Market Dynamics
FIGURE 10: Innovation & Patent Landscape, 2021–2025
FIGURE 11: Clinical Workflow Economics Framework
FIGURE 12: Remote Diabetes Monitoring Program Economics Framework
FIGURE 13: U.S. Remote Diabetes Monitoring Devices Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 14: U.S. Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 15: U.S. Remote Diabetes Monitoring Devices Market Year-wise Growth Curve, 2021–2035
FIGURE 16: U.S. Diabetes Addressable Population and Remote Monitoring Opportunity Map
FIGURE 17: Product Type Segment Market Share Analysis, 2025 & 2035
FIGURE 18: Product Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 19: Real-Time Continuous Glucose Monitoring Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 20: Intermittently Scanned / Flash Glucose Monitoring Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 21: Implantable Continuous Glucose Monitoring Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 22: Connected Blood Glucose Monitoring Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 23: Remote Monitoring Hubs and Multi-Parameter Diabetes Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 24: Patient Type Segment Market Share Analysis, 2025 & 2035
FIGURE 25: Patient Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 26: Type 1 Diabetes Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 27: Insulin-Treated Type 2 Diabetes Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 28: Non-Insulin-Treated Type 2 Diabetes Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 29: Gestational Diabetes and High-Risk Pregnancy Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 30: Prediabetes and High-Risk Metabolic Populations Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 31: Monitoring Model Segment Market Share Analysis, 2025 & 2035
FIGURE 32: Monitoring Model Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 33: Clinician-Prescribed Continuous Remote Monitoring Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 34: Patient-Managed Monitoring with Cloud Sharing Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 35: Structured Remote Patient Monitoring Programs Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 36: Professional and Episodic Glucose Monitoring Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 37: OTC and Direct-to-Consumer Monitoring Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 38: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 39: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 40: Hospitals and Integrated Health Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 41: Endocrinology and Diabetes Specialty Practices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 42: Primary Care Practices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 43: Home Healthcare and Remote Monitoring Providers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 44: Pharmacies, Retail Health and Direct-to-Consumer Channels Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 45: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 46: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 47: West Region U.S. Remote Diabetes Monitoring Devices Market Share and Leading Players, 2025
FIGURE 48: West Region Market Share Analysis by State, 2025
FIGURE 49: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 50: California Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 51: Washington Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 52: Arizona Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 53: Colorado Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 54: Oregon Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 55: Utah Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 56: Nevada Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 57: New Mexico Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 58: Idaho Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 59: Montana Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 60: Wyoming Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 61: Alaska Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 62: Hawaii Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 63: Northeast Region U.S. Remote Diabetes Monitoring Devices Market Share and Leading Players, 2025
FIGURE 64: Northeast Region Market Share Analysis by State, 2025
FIGURE 65: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 66: New York Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 67: Massachusetts Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 68: New Jersey Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 69: Pennsylvania Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 70: Connecticut Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 71: Maine Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 72: Vermont Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 73: New Hampshire Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 74: Rhode Island Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 75: Delaware Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 76: South Region U.S. Remote Diabetes Monitoring Devices Market Share and Leading Players, 2025
FIGURE 77: South Region Market Share Analysis by State, 2025
FIGURE 78: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 79: Texas Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 80: Florida Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 81: Georgia Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 82: North Carolina Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 83: Tennessee Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 84: South Carolina Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 85: Alabama Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 86: Mississippi Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 87: Louisiana Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 88: Arkansas Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 89: Kentucky Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 90: Oklahoma Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 91: Virginia Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 92: Maryland Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 93: West Virginia Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 94: Midwest Region U.S. Remote Diabetes Monitoring Devices Market Share and Leading Players, 2025
FIGURE 95: Midwest Region Market Share Analysis by State, 2025
FIGURE 96: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 97: Illinois Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 98: Ohio Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 99: Michigan Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 100: Minnesota Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 101: Indiana Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 102: Wisconsin Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 103: Missouri Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 104: Iowa Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 105: Kansas Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 106: Nebraska Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 107: North Dakota Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 108: South Dakota Remote Diabetes Monitoring Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 109: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 110: Company Positioning Matrix
FIGURE 111: Key Player Product and Platform Portfolio Benchmarking
FIGURE 112: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 113: Remote Diabetes Monitoring Innovation Roadmap
FIGURE 114: Longer-Wear CGM Technology Roadmap
FIGURE 115: OTC Continuous Glucose Monitoring Opportunity Map
FIGURE 116: AI-Assisted Glucose Interpretation Roadmap
FIGURE 117: Automated Insulin Delivery and CGM Interoperability Landscape
FIGURE 118: Future Market Scenario Analysis, 2026–2035
FIGURE 119: Disruptive Technologies Impact Matrix
FIGURE 120: Future Reimbursement and Coverage Scenario Matrix
FIGURE 121: CGM Adoption Beyond Insulin Users Growth Roadmap
FIGURE 122: OTC and Consumer Monitoring Growth Roadmap
FIGURE 123: Emerging Business Trends Matrix
FIGURE 124: Investment Prioritization Matrix
FIGURE 125: Market White-Space Opportunity Map
FIGURE 126: Strategic Growth Roadmap for U.S. Remote Diabetes Monitoring Device Companies
FIGURE 127: Go-to-Market Strategy Framework
FIGURE 128: Reimbursement and Market Access Strategy Framework
FIGURE 129: State-Level Market Entry Prioritization Matrix
FIGURE 130: Product Positioning and Portfolio Expansion Framework
FIGURE 131: Partnership and Ecosystem Strategy Framework
FIGURE 132: Report Scope and Disclaimer Framework